news

3D tissue models of brain tumours created in brain-mimicking environment

A new platform has the potential to better understand what dictates the invasive behaviour of brain tumours.

Three-dimensional (3D) human tissue culture models of brain cancers in a brain-mimicking micro-environment have been created which could advance the study of brain tumour biology and pharmacological response.

The researchers from Tufts University, US created models that include brain-derived extracellular matrix (ECM) – the network of proteins and amino acids with bound sugars in the brain. Alterations in ECM composition have been associated with brain tumour progression, which in turn alters patterns of genetic and protein expression in the tumour cells.

This shows a doughnut-shaped 3D silk scaffold (represented as a schematic in the background) treated with ECM and seeded with glioblastoma cells. Spherical growths of the tumour cells (~1mm dark spots – indicated by arrow) are observed after 1.5 months (credit: Tufts University).

The ECM-containing 3D matrix in this study has allowed for the propagation and study of primary tumour cells taken directly from the patient and to grow them in an environment more similar to the brain. 

 

Reserve your FREE place

 


Are low affinity or poor TCR yields slowing you down?

Explore how CHO expression of soluble TCRs and TCR affinity maturation workflows via phage, serving as essential building blocks for early-stage TCR-TCE candidate generation.

22 October 2025 | 16:00 PM BST | FREE Webinar

Join Jiansheng Wu, Ph.D. to explore two integrated strategies:

  • High-titer CHO-based expression of sTCRs (~100 mg/L), enabling scalable and high-throughput production
  • Optimized phage display affinity maturation, improving TCR binding by up to ~10,000-fold

Whether you’re starting a new TCR program or optimizing an existing platform, this session will offer actionable strategies to accelerate discovery and improve candidate quality.

Register Now – It’s Free!

 

“The power of this platform is that we can tune the composition of the ECM to find out the role of each component in tumour growth and we can see the effect on tumour cells derived directly from the patient,” said David Kaplan, Stern Family Professor in Engineering. “Another important feature is that we can track the 3D growth of cells with non-invasive two-photon excited fluorescence metabolic imaging.

In other words, we can use non-invasive imaging to assess if they are viable and growing, or stressed and dying, in real-time.”

“With this platform, we have the potential to better understand what dictates the invasive behaviour of brain tumours and screen drugs for their effect on tumour growth of patient-derived cells,” added Disha Sood, first author of the study. “Although it’s a preliminary notion, the ability to maintain viable cultures of patient-derived tumour cells and metabolically track them non-invasively, suggests the possibility of monitoring the cells’ behaviour and drug sensitivity over time, to inform treatment decisions.”

The study was published in Nature Communications.

Related conditions

Related organisations

Related people
,

Leave a Reply

Your email address will not be published. Required fields are marked *